I. M. Viljoen

I. M. Viljoen

Auto-generated profile, based on publicly available information

I. M. Viljoen

Institute for Cellular and Molecular Medicine, and SAMRC Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2015 in Transboundary and Emerging Diseases
Verified
Journal Article
Open access
PDF file
TOT. T. Olivier
T. T. Olivier
IVI. M. Viljoen
I. M. Viljoen
JHJ. Hofmeyr
J. Hofmeyr
GHG. A. Hausler
G. A. Hausler
Wynand Johan GoosenWynand Johan Goosen
Wynand Johan Goosen
SPS. D. C. Parsons
S. D. C. Parsons
Mycobacterium bovis infection, the cause of bovine tuberculosis (BTB), is endemic in wildlife in the Kruger National Park (KNP), South Africa. In lions, a high infection prevalence and BTB mortalities have been documented in the KNP; however, the ecological consequences of this disease are currently unknown. Sensitive assays for the detection of this infection in this species are therefore required. Blood from M. bovis‐exposed, M. bovis‐unexposed, M. tuberculosis‐exposed and M. bovis‐infected lions was incubated in QuantiFERON®‐TB Gold (QFT) tubes containing either saline or ESAT‐6/CFP‐10 peptides. Using qPCR, selected reference genes were evaluated for expression stability in these samples and selected target genes were evaluated as markers of antigen‐dependent immune activation. The abundance of monokine induced by gamma interferon (MIG/CXCL9) mRNA, measured in relation to that of YWHAZ, was used as a marker of ESAT‐6/CFP‐10 sensitization. The gene expression assay results were compared between lion groups, and lenient and stringent diagnostic cut‐off values were calculated. This CXCL9 gene expression assay combines a highly specific stimulation platform with a sensitive diagnostic marker that allows for discrimination between M. bovis‐infected and M. bovis‐uninfected lions.

3 March 2022 in Biochimie
Verified
Journal Article
Open access
IVI.M. Viljoen
I.M. Viljoen
CHC.L. Hendricks
C.L. Hendricks
HMH.L. Malherbe
H.L. Malherbe
MPM.S. Pepper
M.S. Pepper
Clinicians are increasingly using regenerative medicines to repair, replace, regenerate or rejuvenate lost, damaged or diseased genes, cells, tissues or organs. In South Africa, access to these novel gene therapies and cell and tissue-based products is limited. The human leukocyte antigen (HLA) diversity and a paucity of suitable HLA-identical unrelated donors, results in limited access to haematopoietic stem and progenitor cell transplantation (HSPCT). Cell-based products could increase this access. Genetic diversity can also manifest in local or region-specific rare congenital disorders, and in vivo gene therapies hold the promise of developing treatments and cures for these debilitating disorders. South Africa has a disproportionate mortality rate due to non-natural causes, with many surviving with permanent injuries and disabilities. Tissue-engineered cell-based products have the potential to restore many of those affected and improve quality of life and productivity. These factors create an urgency for South Africa to develop regenerative medicines to address the country's unique needs and to provide access to these new and innovative treatment modalities. Achieving this objective requires a well-coordinated effort by multiple stakeholders and role players. A critical component of a regenerative medicine ecosystem is establishing an enabling regulatory framework for these new classes of medicines. Here we provide a brief profile of South Africa, including its genetic diversity, economy, the impact of the burden of disease, health policy and the healthcare system. We address the regulation of medicines, how the existing framework can accommodate regenerative medicines, and the steps needed to establish a future regulatory framework.

5 November 2021 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
IVI M Viljoen
I M Viljoen
MPM S Pepper
M S Pepper
When cells become medicines: A South African perspective

18 February 2025 in South African Medical Journal
Verified
Journal Article
Open access
IVI M Viljoen
I M Viljoen
Michael Sean PepperMichael Sean Pepper
Michael Sean Pepper
Advanced cell-based and gene therapy products emerged during the 1990s as new health product categories for treating and curing previously untreatable or incurable conditions. These products are complex, diverse and therapeutically specific, requiring specialised regulatory frameworks. During the last three decades, several jurisdictions have constructed specific regulatory frameworks to ensure these products’ safety, clinical efficacy and quality. As these are new and disruptive products, these frameworks are continuously evolving. However, South Africa (SA)’s regulatory frameworks for medicines, human biological materials and genetically modified organisms have not kept pace with scientific and technological developments, leaving regulatory gaps. We briefly describe these novel products and their regulatory frameworks, and propose a way forward in SA.